E
Shares of Puma Biotechnology (PBYI) are down 19% after the company reported mediocre breast cancer results from a poster set to be presented at the American Society of Clinical Oncology — ASCO –meeting being held May 29 to June 2, 2015 in Chicago. Puma’s drug known as Neratinib is in a phase 3 trial treating…